<DOC>
	<DOCNO>NCT00233597</DOCNO>
	<brief_summary>The study evaluate safety efficacy new intravenously administer iron drug treat anemia patient hemodialysis .</brief_summary>
	<brief_title>Ferumoxytol Versus Oral Iron Treatment Anemia Hemodialysis Patients</brief_title>
	<detailed_description>This study evaluate efficacy safety intravenous ( IV ) iron ( ferumoxytol ) compare oral iron treatment anemia hemodialysis patient receive erythropoietin . Patients randomize receive either two dos 510 mg intravenous ferumoxytol sequential dialysis session 200 mg oral elemental iron daily three week .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>Male female patient ≥18 year . Chronic hemodialysis . Stable supplemental EPO therapy . Baseline hemoglobin ≤ 11.5 g/dl . Women pregnant breast feeding . Received another investigational drug device within 30 day . Recent parenteral oral iron therapy . Patients active GI bleed acute bleeding within 4 week . Patients cause anemia . Major surgery within 30 day anticipate planned surgery study . Patients active infection . Recent blood transfusion . Patients know allergy iron product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>anemia</keyword>
	<keyword>iron</keyword>
</DOC>